All News
Another biosimilar Adalimumab. SB5 switch in RA, PsA & SpA N=354 No diff in effectiveness Some minor flares. Some changed dose unsure why. #ACR2020 @RheumNow @CRASCRRheum abstr#805 https://t.co/2Zb4H2jBXQ
Janet Pope Janetbirdope ( View Tweet)
Liver damage is NOT an extra-articular manifestation of RA BUT the ff'g factors are associated with liver disease in RA & can complicate management👇@RheumNow #ACR20 https://t.co/RqL69iVJpC
sheila RHEUMarampa ( View Tweet)
It's only now we have choices to warfarin that we can realise the effect of vit K blockade on OA.
Nested case-control (AF pts, UK primary care):
warfarin has risk vs DOAC for end-stage OA (via joint replacement) aOR 1.25
esp knee aOR 1.48
@Tuhina_Neogi #ACR20 ABST0934 @RheumNow https://t.co/XVLG8kIL0W
David Liew drdavidliew ( View Tweet)
Plenary session: Dr Ballal presents data showing #warfarin use incr. risk of knee/hip replacements, compared to #DOACs
- Nest case-control study in UK THIN database
- Risk increases w/ duration of use
- Indicates need for well-powered RCT of vit K in OA
Abs#0934 #ACR20 @RheumNow https://t.co/YyxDjNQEjx
Mrinalini Dey DrMiniDey ( View Tweet)
Amazing to see a plenary by a 1st year fellow @BU_BMC_Rheum - Vit K is important in preventing #OA progression - obs study #Warfarin has higher knee and hip replacement risk compared to #DOACs #ACR20 @RheumNow ABS#0934 https://t.co/0IUS8QvzI4
Bella Mehta bella_mehta ( View Tweet)
Neihulizumab, novel immune checkpoint agonistic ab that binds to human CD162 (PSGL-1), thereby preferentially inducing apoptosis in late stage activated T cells. Phase II trial shows efficacy in PsA, further trials to come. #ABS0894 #ACR20 @RheumNow https://t.co/gzf7epPyNd https://t.co/ArLlCyzLxR
Dr. Rachel Tate uptoTate ( View Tweet)
What is refractory RA? Inability to reach #T2T goals of remission or at least LDA despite various changes of tx. "We should aim at best care for the tx of refractory RA"-Prof.Josef Smolen @RheumNow #ACR20 https://t.co/7Wxjd5t3Oi
sheila RHEUMarampa ( View Tweet)
50% use septra/bactrim in SLE if immunesuppressed. I don’t use it unless if frequent serious infections or bad lungs as I am not convinced about the risk of PCP/PJP v risk of septra with adverse rxns in SLE. I await an admin database to give me the data @RheumNow #ACR20 https://t.co/3s2S9fIUVe
Janet Pope Janetbirdope ( View Tweet)
Abst#0934 by Dr. Ballal at BU looks at the role of vitamin K deficiency in OA development. Warfarin use with 57% increased risk of TKA/THA compared to NOAC, though diminished when accounting for signif practice variation in these patients @Rheumnow #ACR20 https://t.co/PsESoeurKF
Eric Dein ejdein1 ( View Tweet)
MEASURE2 and COAST-W data stratified by TNFi inadequate responders may suggest different axSpA subset (domain?) response to TNFi vs IL17i. Dr. J. Ermann #ACR20 @RheumNow #ACRbest https://t.co/0ZcEIvkuMj
Dr. Rachel Tate uptoTate ( View Tweet)
Interesting data re HCQ decreasing new PAH in Early SSc #scleroderma Not sure I believe it. Confounding, diff subsets get #hydroxycholoroquine due to inflammatory arthritis etc. Maybe a big pragmatic RCT is warranted as PAH is lethal @RheumNow @CRASCRRheum #ACR20 abstr#925 https://t.co/Al81sMGgxI
Janet Pope Janetbirdope ( View Tweet)
Interesting study suggesting decreasing RF titers can be a biomarker to predict radiographic remission.
Will you change your practice to do serial RF measurements? @rheumnow #ACR20 #ACRbest https://t.co/MvxBv0Kdek
k dao KDAO2011 ( View Tweet)
Re Abs#760: Bone erosions in +CCP not predictive of development of IA. You have a pt with no synovitis, but +CCP, small bone erosion on standing foot xray. Do you treat? #ACR20 @Rheumnow
Eric Dein ejdein1 ( View Tweet)
Tell me what do you focus more on in virtual learning? I will try to vary my backgrounds as a virtual home yours! @RheumNow @CRASCRRheum #ACR20
Janet Pope Janetbirdope ( View Tweet)
Nintedanib for RA-ILD? In the INBUILD Trial, pts on Nintedanib did better than PBO, efficacy similar among autoimmune ILDs including RA. @RheumNow #ACR20 @joanbathon https://t.co/I4AJlemIhD
sheila RHEUMarampa ( View Tweet)
Dr Hansen at 3S008 on "Bone for the Holidays": individualize the decision for drug holidays - here are the key questions: #acr20 @Rheumnow https://t.co/lMHtYW4OzE
Eric Dein ejdein1 ( View Tweet)
Which Axial SpA outcome score do you use in clinic as a target to achieve? @RheumNow #ACR20
Dr. Antoni Chan synovialjoints ( View Tweet)
In SpA-paz cohort 80% of axSpA pts achieved R or LDA at one visit, but only 40% maintained this level of disease control. #ABS0893 #ACR20 @RheumNow https://t.co/3MKBKOoNSw https://t.co/pTMJhtfKbU
Dr. Rachel Tate uptoTate ( View Tweet)
OBRI Canadian registry showed real world retention data for Tofa and TNFi are both similar, but RA pts on TNFi w/o MTX d/c drug more compared to those who stay on MTX (does not matter with Tofa if they are on MTX)
Abstr#808 #ACR20 @rheumnow
https://t.co/TDmV0EJTp8
k dao KDAO2011 ( View Tweet)
SEAM-RA: SDAI remission greater in pts on ETN alone vs. MTX alone; ⬆ pts in remission w/ combined tx vs. MTX alone. These may guide tx decisions re withdrawal in well-controlled RA @Rheumnow #ACR20 https://t.co/33GhuMuL3I
sheila RHEUMarampa ( View Tweet)